Fed. Circ. Backs Sanofi In Prostate Cancer Drug Patent Fight

Law360 (August 14, 2019, 6:37 PM EDT) -- The Federal Circuit on Wednesday ruled that a district judge lacked authority to invalidate claims of a patent on Sanofi's prostate cancer drug Jevtana that the company had disclaimed, and that a host of generics makers failed to prove a second patent on the drug is invalid.

The appeals court agreed with Sanofi that because it disclaimed certain claims of one of its patents, which expires in 2030, Judge Michael Shipp of the District of New Jersey was wrong to find those claims invalid. The decision to give up those claims "mooted any controversy" between Sanofi and generics makers including Mylan...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS